summary
Introduced
11/07/2025
11/07/2025
In Committee
03/05/2026
03/05/2026
Crossed Over
03/05/2026
03/05/2026
Passed
03/17/2026
03/17/2026
Dead
Introduced Session
2026 Regular Session
Bill Summary
An act relating to intoxicating substances; providing a short title; creating s. 569.216, F.S.; prohibiting tobacco or nicotine dealers, or their agents or employees, from possessing, selling, possessing with intent to sell, delivering, or giving, directly or indirectly, nitrous oxide on or from the dealer’s licensed premises; providing criminal penalties; providing applicability; providing construction; requiring the Department of Business and Professional Regulation to adopt rules; amending s. 893.03, F.S.; excepting from the list of Schedule I controlled substances certain xylazine animal drug products approved by the United States Food and Drug Administration and used for certain purposes; amending s. 893.13, F.S.; providing criminal penalties and requiring a mandatory minimum term of imprisonment if a person sells, manufactures, or delivers or possesses with intent to sell, manufacture, or deliver xylazine; amending s. 893.135, F.S.; creating the offense of trafficking in xylazine; providing criminal penalties and requiring a mandatory minimum term of imprisonment and fines based on the quantity of the controlled substance involved in the offense; providing effective dates.
AI Summary
This bill, known as "Meg's Law," introduces several changes related to intoxicating substances, primarily focusing on nitrous oxide and xylazine. It prohibits tobacco or nicotine dealers, their agents, or employees from possessing, selling, delivering, or giving away nitrous oxide on their licensed premises, with exceptions for grocery stores and supermarkets, and clarifies that this does not apply to finished food products where nitrous oxide is solely a propellant; the Department of Business and Professional Regulation is tasked with creating rules to prevent its use for intoxication. Additionally, the bill amends existing law to exclude certain U.S. Food and Drug Administration (FDA)-approved xylazine animal drug products from the list of Schedule I controlled substances, while simultaneously creating criminal penalties and mandatory minimum prison sentences for selling, manufacturing, or delivering xylazine, and establishing the offense of trafficking in xylazine with fines and prison terms based on the quantity involved.
Committee Categories
Budget and Finance
Sponsors (1)
Other Sponsors (1)
Fiscal Policy (Senate)
Last Action
Ordered enrolled (on 03/17/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...